Eva-Lotta Allan, an independent director, has over 30 years of corporate, business development and operational experience from the biotechnology industry of private and public companies. She is a Non-Executive Director of Targovax (TRVX) and was previously a board director of Isconova. During her five years as Immunocore’s Chief Business Officer she raised $320 million in a Series A round, established significant strategic partnerships with top pharmaceutical companies and in 2016 she was elected to the Board of the BIA. Eva-Lotta was previously at Ablynx, where she served as Chief Business Officer for seven years taking the company public and structured several complex partnerships with pharmaceutical companies. Eva-Lotta has also held a number of roles in biotech companies including as Senior Director of Business Development and Site Operations (Europe) at Vertex Pharmaceuticals. She has a degree in microbiology from Stockholm University and started her career at the Tumour biology department at the Karolinska Institute in Stockholm.